Browse products
Generic and innovative drugs market in Russia and Ukraine 2011Comparative analysis, reimbursement policies and development forecasts for 2011-2013 |
Our clients say...
The report provides a comprehensive analysis of generic and innovative drugs segments in Russia and Ukraine, with development forecasts for the period until 2013. It was prepared by the team of PMR’s pharmaceutical market analysts together with economy experts.
“We use PMR's services due to their analysts' extensive experience in market analysis, their high quality and level of engagement in the market research carried out for us. We consider PMR a competent and professional company and recommend them as a reliable partner in the area of economic information and market analysis.”
Senior Trade and Investment Adviser, British Embassy in Warsaw
“It's a great pleasure to cooperate with PMR because of its analysts' wealth of experience in understanding the local market. We consider PMR a competent and professional company which helps us conduct our business. I would also like to state that PMR's team is always ready to respond to emerging customer needs. We can recommend it as a reliable partner.”
Business Analyst, Hilti Distribution, Russia
“As a London-based company, with operations abroad, we looked for the best-in-class Market Intelligence supplier. PMR brought us quality reports that improved our CEE market knowledge and understanding.”
Development Manager, GVA Grimley
“PMR provides a good service and is always open to discussion. All reports are well structured & are always on time.”
Member of the Managment Board, SCA Hygiene Products
“Sanofi-Aventis group regularly order PMR's reports and newsletters concerning the Polish pharmaceutical market. We use PMR's services because of the wealth of experience of its analysts in undertaking market analysis and a high level of quality and involvement in the field of market research. ”
General Manager, Sanofi-Synthelabo
“We consider PMR a competent and professional company. PMR analysts understand our needs clearly and their services have fully met our expectations. I strongly recommend the company as a reliable partner in providing economic information and market analysis.”
General Manager, Sanofi-Synthelabo
“PMR reports are a serious contribution to the market overview picture, focusing our attention on key events in the industry as well as highlighting both general and specific market indicators. Together, these components are the base for our future forecasts of construction market development and help us to plan our sales.
”
Market Analyst, Alpha Cement
“PMR's analysts understand our needs well and the standard of their service has always fully met our expectations. We are looking forward to cooperating with PMR in the future as well. ”
Senior Trade and Investment Adviser, British Embassy in Warsaw
This publication is further enhanced by detailed characteristics of factors influencing these segments, focusing on reimbursement policies, pricing policies as well as governmental attitudes towards foreign and domestic pharmaceutical companies.
Countries’ policies with regards to the counterfeit medicines are also included, as well as profiles of the largest generic and innovative drug manufacturers in Russia and Ukraine.
Key report’s sections
Did you know...
“In Russia and Ukraine only the prices of essential medicines are regulated by the state.”
“There is no VAT rate imposed on pharmaceuticals in Ukraine.”
“Under the Russian government's Pharma 2020 programme, domestic production is to account for 50% of the market by 2020.”
“In Russia a 6-year period of data exclusivity took effect in September 2010.”
“Domestic companies in Russia and Ukraine are rather generic.”
“The lists of the best-selling medicines in Russia and Ukraine are dominated by innovative preparations of foreign origin.”
- value of the generic and innovative drugs market in Russia and Ukraine (2007-2013)
- market share of generic and innovative drugs market in Russia and Ukraine
- regulations regarding prices of non-reimbursed and reimbursed medicines
- VAT rates on medicines
- average and official mark-ups for medicines
- reimbursement system and process
- Pharma 2020
- future changes on the generic and innovative drugs market and in the reimbursement segment
- latest and expected changes on reimbursement lists
- drug patent expiry and data exclusivity periods
- best-selling generic and innovative medicines
- largest generic and innovative drug manufactures in Russia and Ukraine
- counterfeit medicines - market share, country policies
Report's strengths
- detailed characteristic of Russia and Ukraine, as well as comparative analysis of them
- development forecasts for generic and innovative drugs market for 2011-2013
- wide scope of analysis, including reimbursement policies, pricing policies, governmental attitudes
Questions answered by this publication
- What is the value of the generic and innovative drugs market in Russia and Ukraine in 2007-2013?
- What are patients and doctors attitudes towards generic and innovative medicines?
- What are the regulations regarding prices of non-reimbursed and reimbursed medicines in Russia and Ukraine?
- How does the reimbursement system function in Russia and Ukraine?
- What are the Pharma 2020 programme's most important assumptions?
- Which pharmaceutical companies are to invest in drug manufacturing in Russia ?
- Which pharmaceutical companies conduct most clinical trials in Russia and Ukraine ?
- How does the reimbursement process look like in Russia and Ukraine?
- Which changes can be expected in the future on the generic and innovative drugs market as well as in the reimbursement segment?
- Which are the best-selling generic and innovative medicines in Russia and Ukraine?
- Which are the largest generic and innovative drugs manufactures in Russia and Ukraine?
Who is the report for?
- executive staff, managers, marketing departments of generic/innovative drugs companies
- firms from the pharmaceutical industry
- foreign firms investing in generic & innovative drugs segment
- consulting, research and analytical firms
- government institutions, embassies
- chambers of commerce, professional organisations
- universities, scientific institutes
- financial institutions (banks, brokerage firms, investment funds)
- private equity funds
Extract from this report
- The lists of the best-selling medicines in Russia and Ukraine are dominated by innovative preparations of foreign origin. Domestic companies are relatively generic. They do not have enough money for investment in new drug development and do not usually, therefore, manufacture innovative preparations.
- The generic drug subgroup is expected to develop at a relatively impressive rate in both Russia and Ukraine between 2011 and 2013. According to our forecasts, this subgroup in Russia will grow by 20% on average per annum, whereas in Ukraine it will develop by 31%, assuming a constant euro to local currency exchange rate. These figures are much higher than those of other CEE countries.
Market commentary by expert
Because of Pharma 2020 programme regulations, designed to support local production, an increasing number of pharmaceutical companies are deciding to open their production facilities in Russia . The total amount invested by pharmaceutical manufacturers in the country could reach at least €1bn, according to our estimates. In our opinion, the domestic production in Russia is to focus mainly on biosimilars and high-standard generics, so the share of innovative medicines in the market, which is one of the lowest in Europe, is not to increase significantly. Also in Ukraine the generic drug segment is to develop faster than the original one in the coming years, i.e. between 2011 and 2013.Agnieszka Stawarska, Pharmaceutical market analyst
Request sample pages/interactive screenshare
-
Report methodology p. 9
-
Executive summary p. 13
-
Characteristics of generic and innovative drug markets in Russia and Ukraine p. 19
-
Comparative analysis p. 19
- Share of Russia and Ukraine as a proportion of generic and innovative drug subgroups in CEE p. 19
- Share of generic and innovative medicines as a proportion of the pharmaceutical market p. 20
- CAGR for generic and innovative medicines for 2011-2013 p. 22
- Reimbursement and pricing policies p. 22
- Key manufacturers and best-selling medicines p. 24
- Drug patent expiry and data exclusivity periods p. 24
-
Russia p. 25
- Main trends and events on generic and innovative drug market p. 25
- Market size p. 31
- Share of pharmaceutical market p. 31
- Market forecasts for 2011-2013 p. 34
-
Ukraine p. 36
- Main trends and events on generic and innovative drug market p. 36
- Market size p. 39
- Share of pharmaceutical market p. 41
- Market forecasts for 2011-2013 p. 44
-
Comparative analysis p. 19
-
Best-selling drugs in Russia and Ukraine p. 47
-
Russia p. 47
- Pharmacies segment p. 47
- Reimbursement segment p. 48
- Hospital segment p. 48
- Ukraine p. 49
-
Russia p. 47
-
Drug patent expiry and data exclusivity periods in Russia and Ukraine p. 51
- Russia p. 51
- Ukraine p. 52
-
Counterfeit medicines in Russia and Ukraine p. 53
- Russia p. 53
- Ukraine p. 54
-
Reimbursement and pricing policies in Russia and Ukraine p. 57
-
Russia p. 57
-
Pricing policies p. 57
- VAT rate p. 57
- Non-essential drugs p. 57
- Vital and essential drugs p. 58
- Reimbursed medicines p. 59
- Drugs on the hospital market p. 60
-
Reimbursement policies p. 61
- Reimbursement system p. 61
- Reimbursement process p. 64
- Latest changes to VED lists p. 67
-
Pricing policies p. 57
-
Ukraine p. 68
-
Pricing policies p. 68
- VAT rate p. 68
- Drug prices p. 68
- Essential medicines p. 70
- Reimbursement policies p. 71
-
Pricing policies p. 68
-
Russia p. 57
-
Key manufacturers in Russia and Ukraine p. 75
- Profiles of selected leading innovative drug manufacturers p. 75
- Profiles of selected leading generic drug manufacturers p. 91
-
Key players in Russia p. 108
-
Largest innovative and generic manufacturers p. 108
- Total market p. 108
- Pharmacy segment p. 109
- Reimbursement segment p. 110
- Hospital segment p. 111
- Oncology segment p. 112
- Major events associated with generic and innovative manufacturers p. 113
-
Largest innovative and generic manufacturers p. 108
-
Key players in Ukraine p. 115
- Largest innovative and generic manufacturers p. 115
- Major events associated with generic and innovative manufacturers p. 117
-
List of graphs p. 119
-
List of tables p. 123
-
About PMR p. 125
-
Contact PMR p. 126
List of graphs
- Market value (€ m) and y-o-y change of the Russian generic drug market, 2007-2013
- Market value (€ m) and y-o-y growth of the Russian innovative drug market, 2007-2013
- Market value (€ m) and y-o-y growth of the Ukrainian generic drug market, 2007-2013
- Market value (€ m) and y-o-y growth of the Ukrainian innovative drug market, 2007-2013
- Share of Russia and Ukraine as a proportion of the generic drug market in CEE, by value, 2009
- Share of Russia and Ukraine as a proportion of the innovative drug market in CEE, by value, 2009
- Share of generic and innovative medicines as a proportion of the pharmaceutical market in Russia and Ukraine, by value, 2009
- Share of generic and innovative medicines as a proportion of the hospital market in Russia and Ukraine, by value, H1 2010
- CAGR for innovative and generic medicines in Russia and Ukraine, 2011-2013
- Share of generic and original medicines as proportion of Russian pharmaceutical market, by value, 2006-2009
- Share of original and generic drugs as proportion of Russian hospital subgroup, by value, H1 2009 and H1 2010
- Russian generic drug market structure, by drug country of origin, 2008 and 2012
- Russian generic drug market structure, by drug category, 2008 and 2012
- Market value (€ m) and y-o-y change of the Russian generic drug market, 2007-2013
- Market value (€ m) and y-o-y growth of the Russian innovative drug market, 2007-2013
- Market value (UAH m) and y-o-y change in unbranded generic, branded generic, original and traditional medicine subgroups in Ukraine, pharmacy sales, January-October 2007-2009
- Market volume (m packages) and y-o-y change in unbranded generic, branded generic, original and traditional medicine subgroups in Ukraine, pharmacy sales, January-October 2007-2009
- Market value (UAH m) and y-o-y change in unbranded generic, branded generic, original and traditional medicine subgroups in Ukraine, hospital sales, Q1-Q3 2008-2009
- Market volume (m packages) and y-o-y change in unbranded generic, branded generic, original and traditional medicine subgroups in Ukraine, hospital sales, Q1-Q3 2008-2009
- Share of generic and innovative drugs as a proportion of pharmacy market in Ukraine, by value, January-October 2007-2009
- Share of generic and innovative drugs as a proportion of pharmacy market in Ukraine, by volume, January-October 2007-2009
- Share of generic and innovative drugs as a proportion of hospital market in Ukraine, by value, H1 2008-H1 2010
- Share of generic and innovative drugs as a proportion of hospital market in Ukraine, by volume, H1 2008-H1 2010
- Market share of domestic and imported generic and innovative medicines in Ukraine, by value, 2007-2010
- Market value (€ m) and y-o-y growth of the Ukrainian generic drug market, 2007-2013
- Market value (€ m) and y-o-y growth of the Ukrainian innovative drug market, 2007-2013
- Price build-up of vital and essential drugs in Russia, 2011
- Drug price breakdown in the reimbursement subgroup in Russia, total DLO, ONSL and 7 nosologies, by value, January-August 2010
- Drug supply state funding system in Russia, 2010
- Sales value and volume in the reimbursement subgroup in Russia, January-August 2009-2010
- Breakdown of sales within the reimbursement subgroup in Russia, by value, January-August 2010
- Drug reimbursement process in Russia – placing of drugs on the DLO list, 2011
- Drug reimbursement process in Russia – drug provision within a DLO subgroup, 2011
- Origin of medicines on the Vital and Essential Drug List in Russia, 2011
- Origin of medicines on the 2011 Vital and Essential Drug List in Russia, 2010
- Breakdown of the Ukrainian pharmacy market by drug price, by value, 2009
- Breakdown of the Ukrainian pharmacy market by drug price, by volume, 2009
- Prices of domestic and imported generic and innovative medicines in Ukraine ($), 2007-2010
- Year-on-year increases in average prices of original and generic medicines in Ukraine, pharmacy market, January-October 2008-2009
- Formula for calculating the price of imported medicine in Ukraine, 2011
- Bayer pharmacy sales in Ukraine ($ m), 2009 and January-October 2010
- Novartis pharmacy sales in Russia ($ m) and their y-o-y change, 2006-2009
- Novartis group pharmacy sales in Ukraine ($ m), 2009 and January-October 2010
- Novo Nordisk total sales in Russia ($ m), 2008-2009
- Nycomed pharmacy sales in Russia ($ m) and their y-o-y change, 2006-2009
- Nycomed pharmacy sales in Ukraine ($ m), 2009 and January-October 2010
- Sanofi-Aventis pharmacy sales in Russia ($ m) and their y-o-y change, 2006-2009
- Sanofi-Aventis pharmacy sales in Ukraine ($ m), 2009 and January-October 2010
- Servier pharmacy sales in Russia ($ m) and their y-o-y change, 2006-2009
- Servier pharmacy sales in Ukraine ($ m), 2009 and January-October 2010
- Berlin-Chemie/Menarini pharmacy sales in Russia ($ m) and their y-o-y change, 2006-2009
- Berlin-Chemie/Menarini pharmacy sales in Ukraine ($ m), 2009 and January-October 2010
- Dr. Reddy’s sales revenues ($ m) and y-o-y change in Russia, FYFY 10
- Egis sales in Russia ($ m) and their y-o-y change, 2006/2007-2009/2010
- Egis sales in Ukraine ($ m) and their y-o-y change, 2006/2007-2009/2010
- Breakdown of Egis sales in Russia, Q4 2008/2009 and Q4 2009/2010
- Pharmacy sales value and volume of Farmak in Ukraine, 2009 and January-October 2010
- Gedeon Richter sales in Russia (€ m) and their y-o-y change, 2007-Q3 2010
- Gedeon Richter sales in Ukraine (€ m) and their y-o-y change, 2007-Q3 2010
- Krka sales in Russia (€ m) and their y-o-y change, 2007-Q3 2010
- Krka sales in Ukraine (€ m) and their y-o-y change, 2007-Q3 2010
- Pharmstandard sales revenues (RUB bn) and y-o-y change in Russia, 2004-Q3 2010
- Breakdown of Pharmstandard sales in Russia, Q1-Q3 2010
- Ranbaxy sales revenues in Russia and Ukraine ($ m) and y-o-y change, 2008-Q3 2010
- Stada sales of generics and branded products in Russia (€ m), 2008-Q3 2010
- Stada sales of generics and branded products in Ukraine (€ m), 2008-Q3 2010
- Teva total sales in Russia ($ m), 2009-2010
List of tables
- The average exchange rates of the rouble and hryvnia to the dollar and euro used for this report, 2007-2010
- Comparison of reimbursement and pricing policies in Russia and Ukraine, 2011
- Drug patent expiry and data exclusivity periods in Russia and Ukraine in comparison with EU countries, 2011
- List of 57 strategically important drugs to be made locally in Russia from 2015
- Top 10 best selling innovative drugs in Russia, by value, pharmacy market, 2009
- Top 10 best selling innovative drugs in Russia, by value, reimbursement subgroup, 2009
- Top 10 best selling innovative and generic drugs in Russia, by value, hospital subgroup, Q3 2009
- Top 10 best selling generic and innovative drugs in Ukraine, pharmacy market, 2009
- Top 10 best selling generic and innovative drugs in Ukraine, pharmacy market, 2010
- Number of beneficiaries and federal budget spending within the ONSL programme in Russia, 2008-2010
- Number of beneficiaries and federal budget spending within the 7 nosologies programme in Russia, 2009-2010
- AstraZeneca clinical trials carried out in Russia and Ukraine, February 2011
- Bayer clinical trials carried out in Russia and Ukraine, February 2011
- Novartis clinical trials carried out in Russia, February 2011
- Novo Nordisk clinical trials carried out in Russia, February 2011
- Sanofi-Aventis clinical trials carried out in Russia and Ukraine, February 2011
- Dr Reddy’s best selling products in Russia (€ m), FY 09 and FY 10
- Gedeon Richter clinical trials carried out in Russia and Ukraine, February 2011
- Pharmstandard best-selling generic and innovative drugs in Russia (RUB m), Q1-Q3 2010
- Teva clinical trials carried out in Russia and Ukraine, February 2011
- Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, total market, 2009
- Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, pharmacy market, 2009
- Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, reimbursement subgroup, 2009
- Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, ONSL and 7 nosologies, 2009
- Top 10 corporations in the reimbursement subgroup in Russia and associated trademarks with the most productive sales, in terms of value, January-August 2010
- Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, hospital market, Q3 2009
- Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, oncology segment, 2009
- Global pharmaceutical manufacturers: examples of investments and agreements pertaining to drug production in Russia, 2009-2010
- Planned investments in pharmaceutical plants in Russia, 2010
- Top 10 generic and innovative pharmaceutical manufacturers in Ukraine, by value, pharmacy market, 2009
- Top 10 generic and innovative pharmaceutical manufacturers in Ukraine, by value, pharmacy market, November 2009-October 2010
- Top 10 generic and innovative pharmaceutical manufacturers in Ukraine, by volume, pharmacy market, November 2009-October 2010
AstraZeneca
Bayer
Berlin-Chemie/Menarini
Darnitsa Pharma
Farmak
Gedeon Richter
GlaxoSmithKline
Janssen-Cilag
Novartis
Novo Nordisk
Nycomed
Octapharma
Pfizer
Pharmstandard
Pharmsyntez
Roche
Sanofi-Aventis
Servier
Teva
Veropharm
and more...
Bayer
Berlin-Chemie/Menarini
Darnitsa Pharma
Farmak
Gedeon Richter
GlaxoSmithKline
Janssen-Cilag
Novartis
Novo Nordisk
Nycomed
Octapharma
Pfizer
Pharmstandard
Pharmsyntez
Roche
Sanofi-Aventis
Servier
Teva
Veropharm
and more...
Generic and innovative drugs market in Russia and Ukraine 2011
Comparative analysis, reimbursement policies and development forecasts for 2011-2013
Choose your version of this product:
| Language / Licence | Single | 5 Users | Corporate | Global |
| English | 1500€ | 2250€ | 3000€ | 3750€ |
Compare licences
- - for the product preservation: saving the product in the memory of one computer belonging to the client;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for the individual use of one person only, who is indicated by the client during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of 2 to 5 computers belonging to the organisation indicated by the client while purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for 2 to 5 people who work for the organisation indicated by the client during purchasing process, and who are in the same country as the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in the same country as the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers can be located in or outside of the country of the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in or outside of the country of the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.